Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $66.07 USD
Change Today +1.82 / 2.83%
Volume 14.9M
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1 North Waukegan Road

North Chicago, IL 60064

United States

Phone: 847-932-7900

Fax:

s in patients with cystic fibrosis, chronic pancreatitis, and various other conditions. Synthroid: Synthroid is used in the treatment of hypothyroidism. The company has the rights to sell AndroGel, Creon, and Synthroid in the United States. Endocrinology Products Lupron (also marketed as Lucrin and Lupron Depot) is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month, and six-month intramuscular injection. Other Products The company’s other products include the following: Duopa and Duodopa: The company’s levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States. Anesthesia Products: Sevoflurane (sold under the trademarks Ultane and Sevorane) is an anesthesia product that the company sells worldwide for human use. Dyslipidemia Products: The company’s dyslipidemia products (TriCor, Trilipix, Niaspan, Simcor, and Advicor) address the range of metabolic conditions characterized by high cholesterol and/or high triglycerides. Zemplar: Zemplar is a product sold worldwide for the treatment of secondary hyperparathyroidism associated with Stage 3, 4, and 5 chronic kidney disease. Marketing, Sales, and Distribution The company utilizes a combination of commercial resources, regional commercial resources, and distributorships to market, sell, and distribute its products worldwide. The company directs its primary marketing efforts toward securing the prescription, or recommendation, of its brand of products by physicians, key opinion leaders, and other health care providers. Managed care providers (health maintenance organizations and pharmacy benefit managers), hospitals, and state and federal government agencies (the United States Department of Veterans Affairs and the United States Department of Defense) are also primary customers. The company also markets directly to consumers themselves, although in the United States all of the company's products must be sold pursuant to a prescription. In 2014, the company’s products were sold in approximately 170 countries. The company’s products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from company-owned distribution centers and public warehouses. In the United States, the company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies and patients. In 2014, three wholesale distributors (McKesson Corporation; Cardinal Health, Inc.; and AmerisourceBergen Corporation) accounted for all of the company’s sales in the United States. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Research and Development Activities The company spent approximately $3.3 billion on research to discover and develop new products, indications, and processes and to improve existing products and processes in 2014. Regulation The company’s operations are affected by trade regulations in various countries that limit the import of raw materials and finished products and by laws and regulations that seek to prevent corruption and bribery in the marketplace (including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, which provide guidance on corporate interactions with government officials) and require safeguards for the protection of personal data. The company is also subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-kickback and false claims laws in the United States. History AbbVie Inc. was incorporated in Delaware in 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $66.07 USD +1.82

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $48.32 USD -0.14
Amgen Inc $167.91 USD -1.26
Bristol-Myers Squibb Co $65.80 USD -0.20
Eli Lilly & Co $71.58 USD -0.82
Medtronic PLC $77.61 USD -0.89
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 57.2x
Price/Sales 5.1x
Price/Book -- Not Meaningful
Price/Cash Flow 56.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.